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Autoimmune and autoinflammatory diseases are rare but often devastating disorders,
underpinned by abnormal immune function. While some autoimmune disorders are
thought to be triggered by a burden of infection throughout life, others are thought to
be genetic in origin. Among these heritable disorders are the type I interferonopathies,
including the rare Mendelian childhood-onset encephalitis Aicardi-Goutières syndrome.
Patients with Aicardi Goutières syndrome are born with defects in enzymes responsible
for nucleic acid metabolism and develop devastating white matter abnormalities
resembling congenital cytomegalovirus brain infection. In some cases, common
infections preceded the onset of the disease, suggesting immune stimulation as a
potential trigger. Thus, the antiviral immune response has been actively studied in an
attempt to provide clues on the pathological mechanisms and inform on the development
of therapies. Animal models have been fundamental in deciphering biological mechanisms
in human health and disease. Multiple rodent and zebrafish models are available to study
type I interferonopathies, which have advanced our understanding of the human disease
by identifying key pathological pathways and cellular drivers. However, striking differences
in phenotype have also emerged between these vertebrate models, with zebrafish models
recapitulating key features of the human neuropathology often lacking in rodents. In this
review, we compare rodent and zebrafish models, and summarize how they have
advanced our understanding of the pathological mechanisms in Aicardi Goutières
syndrome and similar disorders. We highlight recent discoveries on the impact of
laboratory environments on immune stimulation and how this may inform the
differences in pathological severity between mouse and zebrafish models of type I
interferonopathies. Understanding how these differences arise will inform the
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improvement of animal disease modeling to accelerate progress in the development of
therapies for these devastating childhood disorders.
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INTRODUCTION
Type I interferons (IFNs) play an essential role in the antiviral
innate immune response—protecting the host from productive
viral infection before the development of adaptive immune
response to pathogens (1, 2). Upon detection of foreign
nucleotides in the host, canonical type I IFN signaling activates
a number of pathways—ultimately leading to upregulation of
interferon-stimulated genes (ISGs) and wide-ranging effects
comprising host defense (2, 3). However, while type I IFN
signaling is protective in response to active viral infection,
aberrant activation of this pathway has been suggested to occur
in autoinflammatory disease, triggered by genetic mutations in
the host (1, 4).
The association between upregulation of type I IFN and
autoimmune/autoinflammatory disease was first proposed
following the observation of overlapping phenotypes between
such disorders and congenital HIV-1 infection (5). Following
subsequent genetic characterization, a distinct grouping of
disorders has emerged, in which disturbance of the homeostatic
control of type I IFN response—and subsequent upregulation of
ISGs—due to Mendelian mutations is central to pathogenesis (4, 6,
7). Now collectively referred to as the type I interferonopathies, this
group includes the chronic autoimmune disease systemic lupus
erythematosus (SLE), the inherited encephalopathy Aicardi-
Goutières syndrome (AGS) and a range of often rare but
devastating conditions (4).
In this review, we focus specifically on AGS and the closely
related RNaseT2-deficient leukodystrophy. Alongside the
prominent inflammatory phenotype typical of type I
interferonopathies, these disorders present with devastating
neurological phenotypes which are not only debilitating to
patients but have proven particularly difficult to recapitulate in
animal models (8). Accurate, valid animal models are essential
for the development of novel therapies: thus far, the translational
impact of animal models of interferonopathies has been vastly
limited by the lack of neuropathology in preclinical settings.
Here, we summarize the human phenotype of AGS and
RNaseT2-deficient leukodystrophy and provide a brief
overview of the human genetics involved in these disorders.
For each of these interferonopathy-linked genes, we analyze the
relevance of existing animal models to the human condition,
comparing and contrasting models of different species. Finally,
we propose that key environmental modulators—namely, early
life viral exposure—may account for the differences in phenotype
across species and suggest how this theory could be tested to
inform our understanding of the human condition.
THE GENETICS OF AICARDI–GOUTIÈRES
SYNDROME AND RELATED
INTERFERONOPATHIES
Of all the conditions now recognized as type I interferonopathies,
AGS is perhaps among the most extensively characterized.
Although rare, patients with this progressive encephalopathy
present with severe intellectual, speech and motor disability in
infancy—often mimicking aspects of congenital viral infection
(7, 9). Clinical phenotypes become apparent within the first
year of life for most patients, with disease onset thought to occur
in utero in up to one in five patients (10). Although symptoms
and severity vary, most individuals with AGS present with one of
several “classical” clinical presentations—most commonly
including white matter disease, intracranial calcification
and microcephaly—although additional genetic subtype-
specific pathological hallmarks have also been characterized
(Table 1) (7). Regardless of mutation, patients with AGS show
consistent and significant upregulation of type I IFN and
ISG expression—supporting their classification as a type
I interferonopathy.
To date, seven genes have been identified as the genetic trigger
for different subtypes of AGS (AGS1–7), each of which encode
proteins involved in detecting or metabolizing nucleic acids and
particularly in restricting reverse transcription (see Figure 1) (7).
Along with the viral-like phenotype of AGS patients, this has led
to the hypothesis that type I IFN is triggered by the accumulation
of self-derived nucleotides from endogenous retroelements in
some AGS patients (44). In support of this, preclinical and initial
clinical studies have suggested that reverse transcriptase
inhibitors (RTIs) may have clinical benefits in AGS (7, 45, 46).
However, the effects of RTIs on neurological phenotype remains
unclear: firstly, because the animal models utilized in these
preclinical studies do not develop neuroinflammation even
before treatment and, secondly, because the patients enrolled
in clinical trials had significant impairments at baseline, such
that improvement was not to be expected trials (7, 46). Arguably
the core component of disease, much remains to be understood
about the neuropathology of AGS: how it develops, why it varies
between patients and, ultimately, how it can be treated.
In addition to AGS1–7, mutations in RNASET2 have been
linked to a closely related interferonopathy in human patients,
with a similar neurological and inflammatory phenotype:
RNaseT2-deficient leukoencephalopathy. Much like in AGS,
Abbreviations: AGS, Aicardi Goutières syndrome; CRISPR, clustered regularly
interspaced short palindromic repeats; DNA, deoxyribonucleic acid; HIV, human
immunodeficiency virus 1; IFN, interferon; ISG, interferon stimulated gene; LINE-
1, long interspersed nuclear element 1; MRI, magnetic resonance imaging; RNA,
ribonucleic acid; RTI, reverse transcriptase inhibitor; SLE, systemic
lupus erythematosus.
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patients with mutations in RNASET2 present with psychomotor
impairments, micro- or normocephaly and spasticity—
mimicking congenital cytomegalovirus infection (34, 35). As
with AGS-associated genes, RNaseT2 is involved in the sensing
of nucleic acids—either endogenous or virally derived. Thus, we
believe discussion of RNaseT2-deficient leukodystrophy
alongside AGS in the context of interferonopathy here
is warranted.
Recapitulating AGS and RNaseT2-deficient leukoencephalopathy
phenotypes in animal models could provide crucial insights
into neuropathology and invaluable preclinical therapy
development. However, as mentioned above, the translational
impact of these models remains minimal—largely as many of
these models do not develop neurological abnormalities.
Understanding why preclinical models have failed to fully
recapitulate the human phenotype is essential to furthering our
understanding of interferonopathy progression.
ANIMAL MODELS OF
INTERFERONOPATHIES
With such distinct and well-documented genetic underpinnings,
it is unsurprising that preclinical research in AGS and related
interferonopathies has focused on monogenic animal models.
Much of this research has been conducted in rodent and
zebrafish models of disease—with mouse models largely
dominating the field until recent years. The overall merits of
these model organisms in interferonopathy and, specifically,
leukodystrophy research have been reviewed elsewhere (8).
TABLE 1 | Summary of animal model phenotypes in interferonopathy research.
Human Mouse Zebrafish
TREX1 (AGS 1) [loss-of-function]





Neurological White matter abnormalities and intracranial calcification;
abnormal sensorimotor development (7)
None reported (14) [n/a]
RNASEH2A, -B and -C (AGS2, -3 and -4) [loss-of-function]
Immunological Upregulation of ISG transcripts in some patients (10, 11) Evidence of upregulated ISG
expression (15–17)
[n/a]
Neurological White matter abnormalities and intracranial calcification;
abnormal sensorimotor development; non-syndromic
spastic paraparesis (7, 18, 19)
None reported (16) [n/a]
SAMHD1 (AGS5) [loss-of-function]
Immunological Upregulation of ISG transcripts (10, 11) Upregulation of ISG
transcripts, not reflected at
protein level (20–22)
Upregulation of type I IFN, ISGs, and other genes involved
in innate immunity (23)
Neurological White matter abnormalities and intracranial calcification;
abnormal sensorimotor development; intracerebral, large
vessel disease (intracerebral hemorrhage and infarcts)
(7, 24)
None reported (20–22) Cerebral hemorrhage; cerebral oedema (23)
ADAR1 (AGS6) [loss-of-function]
Immunological Upregulation of ISG transcripts (10, 11) Upregulation of ISG
transcripts; embryonic lethal
(25–30)
Increased expression of ISGs and other genes involved in
innate immunity (23)
Neurological White matter abnormalities and intracranial calcification;
abnormal sensorimotor development; bilateral striatal
necrosis; non-syndromic spastic paraparesis (7, 19, 31)
None reported; embryonic
lethal (25–27)
Severe developmental defects (23)
IFIH1 (AGS7) [gain-of-function]
Immunological Upregulation of ISG transcripts (10) Severe multiorgan
inflammation; upregulated ISG
expression (32)
No published gain-of-function mutation; loss-of-function
mutation restores expression of immune-regulated genes to
wild type levels in mutants with upregulated interferon
response (33)
Neurological White matter abnormalities and intracranial calcification;
abnormal sensorimotor development; non-syndromic
spastic paraparesis (7, 19)
None reported (32) None reported (33)
RNASET2 [loss-of-function]
Immunological Phenotype mimicking cytomegalovirus infection (34)
Upregulation of ISGs in some patients (18, 35)
Neuroinflammation [see below];
no evidence of systemic
inflammation (36)
Upregulation of ISG transcripts including isg15 (37, 38)






White matter abnormalities beginning during embryogenesis
(microglial dysfunction); locomotor defects (37, 38)
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Here, we provide an overview of the phenotypes of currently
available mouse and zebrafish models by gene, focusing on their
relevance to the human clinical presentation (Table 1).
TREX1 (AGS1)
With roles in antiviral response and metabolism of intracellular
RNA, the gene encoding 3’ repair exonuclease, TREX1, was the
first to be linked to AGS (12, 39). Accordingly, the phenotype of
Trex1-deficient mice is perhaps the most extensively
characterized of all AGS-associated models. Trex1-/- mice
develop multiorgan inflammation—predominated by
inflammatory myocarditis—and limited survival due to
circulatory failure (13, 14). Crucially, however, Trex1-/- mice do
not display any evidence of neuropathology—in fact, the brain
appears to be one of the few tissues which does not develop an
inflammatory phenotype (14). It is unclear why the brain appears
to be protected from pathology in this manner—limiting the
utility of Trex1-deficient mice as a preclinical model of AGS.
In addition to their links with AGS, mutations in TREX1 (and
SAMHD1, discussed below) have been associated with other
autoimmune disorders which are characterized by a more
widespread inflammatory phenotype and less prominent
neurological involvement (4, 47–50). Although clinical overlap
between SLE and AGS has been reported in some patients, it
remains unclear why some patients with TREX1 mutations
develop a phenotype dominated by neuroinflammation and
others do not (5, 51–53). Therefore, Trex1-/- mice may better
reflect the SLE phenotype and should therefore be considered a
more useful model of this disorder, rather than AGS.
Perhaps the development of complementary zebrafish models
could further elucidate the role of TREX1 in AGS neuropathology.
Human TREX1 and TREX2 are co-orthologous with zebrafish genes
trex3 and trex4. Interestingly, trex3 expression is upregulated in
zebrafish injected with type I IFN, suggesting this gene is an ISG and
may act as a functional orthologue to TREX1 (54). Hence,
experimental manipulation of trex3 expression may be
informative about the role of its human equivalent in AGS.
RNase H2A, -B, and C (AGS 2, 3, 4)
Composed of three subunits, the ribonuclease H enzyme
(RNaseH2) complex has roles in DNA synthesis and repair,
including LINE-1 retrotransposition (44). Together, mutations
in RNaseH2A, -B and -C account for over 50% of cases of AGS—
demonstrating a clear role for this gene in interferon-induced
pathogenesis (55). While characterization of an rnaseh2 zebrafish
model is yet to be published, several mouse models have been
generated to dissect the role of RNaseH2 in the neurological and
inflammatory phenotype of AGS—yet, none have fully
FIGURE 1 | Type I interferonopathy-associated genes are involved in the sensing and metabolism of viral RNA. Genes linked to AGS and RNaseT2-deficient
leukoencephalopathy are thought to encode proteins involved in the restriction of reverse transcription of both viral- and endogenous retroelement-derived DNA. The
IFIH1 gene product, MDA5, is involved in the antiviral response through the recognition of dsRNA and subsequent production of type I interferon. With interferon-inducible
expression, ADAR1 acts as a suppressor of type I IFN signaling through its RNA editing activity. RNaseT2 is a lysosomal hydrolase involved in RNA metabolism.
SAMHD1 limits reverse transcription though degradation of deoxynucleotides necessary for complementary DNA strand formation. Among other roles in DNA synthesis
and repair, RNaseH2 is thought to degrade the RNA component of DNA-RNA hybrids formed during reverse transcription. Finally, TREX1 is involved in the regulation of
the interferon-stimulatory DNA response after viral infection through metabolism of virally derived nucleotides. In the absence of functioning AGS or RNaseT2 proteins,
accumulation of immunostimulatory deoxyribo- and ribonucleotides may trigger upregulation of type I interferon pathway (6, 7, 12, 25, 32, 37, 39–43).
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recapitulated the human disease (15–17, 56, 57). While
hypomorphic models (with point mutations in single subunits)
have demonstrated some upregulation of ISG expression,
perhaps the model with the greatest face validity is the
RNaseH2DGFAP mouse—a brain-specific knockout, lacking
RNase H2 specifically in astrocytes and neurons (15–17).
Astrocytes cultures from these animals demonstrated increased
ISG transcript levels, along with signs of DNA damage and
premature senescence—consistent with a type I interferon
response (16). However, this was not accompanied by any
evidence of neuroinflammation or overt neurological
phenotype in the whole animal—failing to recapitulate the key
components of human disease.
SAMHD1 (AGS5)
In accordance with the reverse transcription theory of AGS
pathogenesis, SAMHD1 encodes a protein involved in restricting
viral DNA synthesis—degrading the intracellular deoxynucleotides
needed for reverse strand formation and therefore limiting both
viral DNA replication and retrotransposon transcription (7, 58, 59).
Mutations in SAMHD1 are thought to account for around 13% of
AGS mutations and have been linked to several other
interferonopathies—demonstrating a clear link between SAMHD1
dysfunction and autoimmunity (4, 10, 60).
While there is considerable variation in the clinical
phenotypes of AGS patients—regardless of their genotype—
patients with SAMHD1 mutations present with a somewhat
distinct phenotype, with intracerebral large vessel disease being
a hallmark of pathology which can present as cerebral arterial
stenosis, intracerebral hemorrhage or other cerebrovascular
abnormalities such as moyamoya presentation (7). Cerebral
hemorrhage has been recapitulated by zebrafish models,
following knockdown of samhd1 using antisense morpholinos
(23). These animals present with swelling of the hindbrain
ventricle and cerebral hemorrhage during embryogenesis. This
neurophenotype is accompanied by upregulated expression of a
panel of genes known to be involved in IFN-mediated antiviral
response—including isg15 (an interferon-stimulated gene known
to be involved in the zebrafish immune response)—suggesting
knockdown of samhd1 induces an interferon response in
zebrafish models mimicking the human state (61).
In contrast, SAMHD1 knockout mice fail to develop both the
neurological and immunological components of the human AGS
neurological phenotype—remaining healthy into adulthood with
no evidence of autoinflammatory pathology (20–22). While ISG
transcripts are upregulated in these animals, this is not mirrored
at a translational level—with no observable difference in ISG
products or IFN proteins across multiple tissues, alongside a lack
of inflammatory pathology in the heart and skin.
It is curious that reduced (but not abolished) expression of
samhd1 in zebrafish leads to a more extreme neurological
phenotype than complete knockout in mouse models. It has
been suggested that the function of murine Samhd1 may differ
from that of the human and zebrafish orthologue—perhaps with
lesser involvement in the innate immune response to nucleic
acids in mice than the other species (22). Conversely, it is
possible that a compensatory mechanism exists in the mouse that
is not present in humans or zebrafish, suppressing the IFN
response and preventing the formation of a neurological
phenotype as might be expected in knockout mice (23).
Nonetheless, the finding that zebrafish models of AGS better
recapitulate the human SAMHD1-linked neurological
phenotype relative to their murine counterparts raises
interesting questions about the use of these species in
interferonopathy modeling.
ADAR1 (AGS6)
Like SAMHD1, ADAR1 has been proposed to be involved in the
restriction of reverse transcription due to its intrinsic RNA
editing activity (7). Unlike other ADAR isoforms, ADAR1
expression is interferon-inducible, with a prominent role as a
suppressor of type I IFN signaling (6, 25, 40). Both mouse and
zebrafish models have been generated to dissect the role of
ADAR1 in interferonopathy pathology, with limited success.
Several Adar1 knockout and mutant lines have been
investigated in mice, many of which die during embryogenesis
or early life (25–30). Characterization of embryonic lethal Adar
null mutants revealed upregulation of ISG expression, which
could be partially rescued through mutation of Ifnar1 (IFN-a
and -b receptor 1) and fully rescued by mutation of MAVS—a
key adaptor protein involved in antiviral response—suggesting
knockout of Adar induces a type I IFN response (25, 28).
A similar immunological phenotype has been reported in
zebrafish with impaired expression of the zebrafish orthologue of
ADAR1, through the use of antisense morpholinos (23).
Although not fully characterized, adar ATG and splice
morphants display increased expression of a panel of innate
immune genes, including the ISGs isg15, irf7, and stat1b.
In contrast to animal models focusing on other AGS-
associated genes, it seems that zebrafish and mouse models of
ADAR1 dysfunction present with phenotypes that are, in many
instances, arguably more severe than the human condition. It is
notable that, in mammals, three proteins exist within the ADAR
gene family: two of which are thought to have roles in A-to-I
editing within the central nervous system (ADAR1 and ADAR2),
while the other is thought to have no intrinsic enzymatic activity
(26, 27, 62, 63). While each of these expresses discrete functions
and ADAR1 is thought to be responsible for most of the editing
activity, it has been suggested that ADAR2 may be able to
partially compensate in human patients with ADAR1
mutations—preventing the severe phenotypes and embryonic
mortality observed in zebrafish and mouse models (63, 64).
Although mice and zebrafish also possess three ADAR genes, it
is possible that the distribution of enzymatic activity across these
three isoforms differs across species, such that the remaining
proteins are less able to compensate for the loss of functioning
ADAR1/adar in the models discussed above than in humans
(65). Any differences in ADAR function across species in the
context of interferonopathies remain speculative at this stage—
nonetheless, the disparity between zebrafish, mouse and human
phenotypes here highlights an extra layer of complexity when
modeling even monogenic disorders.
Rutherford et al. Interferonopathy Models: Zebrafish Versus Mice
Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 6236505
IFIH1 (AGS7)
Of all of the AGS-associated genes, mutations in IFIH1 were
most recently identified in AGS patients—with IFIH1 being the
only AGS-associated gene to present with gain-of-function
mutations in patients. IFIH1 encodes the RIG-I-like receptor
MDA5, which has a prominent role in antiviral defense through
the detection of double stranded RNA and downstream
activation of type I interferon response (32, 41). Patients with
IFIH1 mutations develop phenotypes typical of AGS, including
severe developmental delays, progressive microcephaly and
upregulation of ISG transcription (Table 1) (41).
The role of MDA5 in activation of the innate immune
response is supported by published work with zebrafish loss-
of-function crispants (33). While lack of functioning mda5 alone
did not lead to significant changes in innate immunity-associated
genes (including irf7 and stat1b), mutation of mda5 was
sufficient to restore expression of these genes to wildtype levels
in animals with an already upregulated interferon response
(zbtb24 mutants) (33). The immune phenotype of these zbtb24
mutants is thought to be triggered by increased levels of double
stranded RNA transcripts in the cytoplasm—supporting the role
of Mda5 as an essential mediator of the innate immune
activation in response to RNA. However, to our knowledge, no
zebrafish models of mda5 gain-of-function—the genotype of
greatest relevance to AGS—have been published thus far.
In contrast, MDA5 gain-of-function rodent models have been
characterized. In accordance with the autoimmune phenotype of
patients, Ifih1 mutant mice develop severe multiorgan
inflammation—including nephritis and calcification of the liver
—alongside reduced survival and upregulated expression of IFN
and ISG transcripts (32). However, despite such a severe systemic
inflammatory response, an overt neuroinflammatory phenotype
has not been reported in Ifih1 rodent models. Thus, until a gain-
of-function zebrafish model is generated with a view to
recapitulating AGS, much remains to be understood regarding
the role of IFIH1 in interferonopathies, particularly in relation
to neuropathology.
RNASET2
Much like the monogenic mutations linked to AGS, the
association of mutations in RNaseT2 with a similar
interferonopathy has led to the generation of animal models
exploring the function of this gene. As previously discussed,
patients with mutations in RNaseT2 present with clinical and
radiological phenotypes closely mimicking those seen in AGS—
suggesting the possibility of shared pathogenesis (35). Indeed,
similar to AGS-linked genes, the lysosomal enzyme RNaseT2 is
involved in restriction of reverse transcription through the
metabolism of virally- or endogenously-derived single-stranded
RNA (Figure 1) (42).
While no RNaseT2 mouse models have been published, both
zebrafish and rat models have variably recapitulated the human
phenotype. RNaseT2 knockout rats develop a robust
neuroinflammatory phenotype—with enlarged prefrontal cortex
and hippocampus, accompanied by increased numbers of reactive
astrocytes in the hippocampus (36). Accordingly, these animals
show impaired object recognition, but are otherwise viable—with
normal life expectancy and motor function. However, the overall
inflammatory phenotype of these animals remains unclear—no
evidence of systemic inflammation has been reported in
RNaseT2-/- rats. Crucially, these animals also fail to recapitulate
the key hallmark of RNaseT2-deficient leukodystrophy pathology:
white matter abnormalities.
White matter lesions, subcortical cysts and calcification are
centra l to the pathogenes i s o f RNaseT2-defic ient
leukodystrophy, contributing to the devastating psychomotor
impairments observed in the clinic (34). Use of magnetic
resonance imaging (MRI) has demonstrated that adult rnaset2
mutant zebrafish develop robust white matter lesions, with
further work suggesting white matter abnormalities begin
during zebrafish embryogenesis, as reflected in microglial
dysfunction just five days post-fertilization (37, 38). Similar to
patients, rnaset2 mutant zebrafish display locomotor defects
from early development into adulthood and significantly
reduced survival (38). Beyond the neurological phenotype,
rnaset2 mutants display increased expression of ISG transcripts
—including isg15—mimicking the viral-like phenotype of
patients (37).
Thus, while only three of the genes discussed above have been
modelled in zebrafish to date, it would seem that fish models are
able to recapitulate neurological phenotypes of type I
interferonopathies, while their rodent counterparts are
somewhat spared from neuropathology. Of each of the rodent
models utilized above, only the RNaseT2 knockout rat develops
evidence of neuroinflammation, and even this appears to be
limited to the hippocampus—with overall white matter integrity
and sensorimotor function preserved. It is notable that rats
possess only a single-copy of RNaseT2, while mice possess an
additional copy of the RNaseT2-encoding gene—highlighting
the importance of assessing the genetic background of the model
system before considering its relevance to the human phenotype
(36). Nonetheless, the consistent differences between zebrafish
and murine models pose interesting challenges for
interferonopathy modeling in these species.
WHAT CAN WE LEARN FROM
INTERSPECIES DIFFERENCES IN ANIMAL
MODELS OF INTERFERONOPATHY?
Despite the crisis in translation of preclinical research into
therapeutic advances, rodent models have remained at the
forefront of immunological research for decades (66–68). Mice
have long since been considered of sufficient evolutionary
similarity to humans to act as a relevant model of research. Yet,
in the field of interferonopathy modeling, it seems the zebrafish—a
species more evolutionarily distant from humans—arguably better
recapitulates clinical phenotypes, with particular relevance to the
neurological symptoms at the core of AGS and RNaseT2-deficient
leukodystrophy. What, then, is the missing link between zebrafish
and mice in interferonopathy research?
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Age of Assessment
One crucial consideration when assessing the face validity of
preclinical models—particularly those which model diseases
which manifest almost consistently during early life—is the age
at which the animals are screened for pathology (10). In patients
with AGS, clinical phenotypes frequently emerge during the first
year of life, with prenatal disease onset thought to occur in up to
one fifth of patients, suggesting analysis of disease phenotypes
may be most relevant during early development (10). However, it
should be noted that, for the models discussed above, mouse
phenotypes were assessed postnatally or in early adulthood,
while zebrafish were often screened during embryogenesis or
larval stages. This is, in part, due to the intrinsic features of the
species used: due to their ex utero development and transparency
during embryogenesis, zebrafish can provide unique insights into
developmental pathology. In contrast, mice are often raised into
adulthood before culling, in order to allow for more
comprehensive assessment of relevant phenotypes.
It is possible, therefore, that the mouse models discussed
develop fetal phenotypes just as the zebrafish do, but these are
compensated for at later stages and therefore missed during
postnatal screening. Indeed, in human patients, AGS is often
characterized by a period of pronounced symptomatic
deterioration followed by stabilization and—in rare cases—small
improvements (7, 69). However, patients rarely make a complete
functional recovery, with the neuropathology and white matter
lesions which first presented during early development observable
throughout life. Likewise, longitudinal characterization of the
rnaset2 mutant zebrafish revealed white matter lesions and
behavioral abnormalities which persisted into adulthood (37,
38). It is, therefore, unlikely that any fetal neuropathology in
mice would fully rectify throughout development such that adults
appeared neurologically normal at screening. Nonetheless, the
discrepancy between mouse and zebrafish phenotypes highlights




When assessing the validity of any animal model in
recapitulating clinical phenotypes, it is important to consider
the relevance of the model organism to patient genetics. Like
many other interferonopathies, AGS and RNaseT2-deficient
leukoencephalopathy are monogenetic disorders—as such, each
of the animal models previously discussed disrupt the function or
expression of a single gene linked to the human condition.
However, across mice and zebrafish, a range of genetic
strategies have been utilized to generate disease models. It is
notable that the mouse models discussed here have employed
knockout approaches to mimic the loss-of-function mutations
seen in many patients (excluding IFIH1)—resulting in animals
with little-to-no expression of the relevant gene. As discussed
elsewhere, these models have little relevance to the human
genotype—with most patient mutations resulting in reduced
expression of functioning or malfunctioning protein. Crucially,
such extreme genotypes may limit the translational impact of
these models in the development of therapies—particularly those
which aim to reintroduce target proteins, such as enzyme-
replacement or gene therapy. Against a constitutive knockout
background, the reintroduced protein may initiate an immune
response after being recognized as foreign—as has been reported
in preclinical models of a closely related leukodystrophy,
Alexander’s disease (70). In contrast, patients with some
endogenous expression of these genes are perhaps less likely to
develop an immune response to reintroduced proteins—making
it difficult to predict the efficacy of such treatments based on
these preclinical mouse models (8). Unlike their murine
counterparts, many of the genetic tools used to generate
zebrafish models of interferonopathies—such as antisense
morpholino oligonucleotides and CRISPR/Cas9 gene editing—
result in genotypes frequently more relevant to the human
condition, by knocking down gene expression or generating
mutated protein (rather than a constitutive knockout) (23, 38).
One might expect animals with a complete lack of relevant
gene expression to present with an arguably more severe
phenotype than those retaining some level of protein (whether
this be reduced levels of functioning protein or dysfunctional
enzyme). Indeed, this seems to be the case when considering
ADARmouse models—with animals with point mutations in the
ADAR gene surviving slightly longer than complete knockouts
(25–30). However, the same seems not to apply to animal models
of SAMHD1 and RNaseT2 dysfunction. For each of these genes,
constitutive knockout rodents fail to fully recapitulate the
immune phenotypes reported in human conditions—with
overtly normal development and survival (20–22, 36). In
contrast, samhd1 and rnaset2 defective zebrafish develop
robust neurological phenotypes relevant to the human
condition—with samhd1 models developing cerebral
hemorrhage, while rnaset2 mutants acquire white matter
abnormalities and locomotor dysfunction (23, 37, 38). For each
of these models, the genetic strategies utilized preserve some level
of protein expression and, yet, their phenotypes are more severe
—and arguably more relevant to the human condition—than
their murine counterparts.
However, it should be noted that several studies in zebrafish
have reported poor correlation between the phenotypes of
mutants (i.e. those generated using CRISPR/Cas9) and
morphants (those generated by morpholino)—with morphants
often presenting with more severe phenotypes than mutants,
even in the absence of any observable off-target effects (71, 72). In
addition, subsequent research has suggested that the use of
morpholinos themselves may induce an interferon-like
response, with upregulation of ISGs reported across multiple
published morphants (73). As such, it is possible that intrinsic
limitations of morpholino-induced knockdown may account for
the more severe phenotypes observed in samhd1 zebrafish
models relative to their murine counterparts (20–23).
However, these findings still cannot account for the phenotypic
differences between RNaseT2 knockout rats and rnaset2 mutant
zebrafish—the latter of which has been validated using both ENU
mutagenesis and CRISPR/Cas9 gene editing and bred to produce
stable lines with comparable phenotypes (37, 38). As such,
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differences in methodology cannot entirely account for the
differences in neurophenotypes reported in rodent and
zebrafish models of type I interferonopathies.
In addition to the genetic modifications utilized to generate in
vivo models, it should also be noted that there are substantial
differences in the genetic backgrounds of zebrafish and mice used
in experimental settings. For example, laboratory mice are highly
inbred to reduce variability—particularly when characterizing
phenotypes associated with single gene knockout—resulting in a
single line which does not reflect the substantial genetic
variability seen in human populations. In contrast, zebrafish
are relatively outbred, leading to an accumulation of
polymorphisms that vary from one animal to the next and
perhaps more closely mimic the complex genetic make-up of
humans than mice. The combined effect of these mutations may
well act as a phenotypic modifier—resulting in intraspecies
variability in pathology, as is seen in human AGS patients with
mutations in the same gene (18). However, any increased
variation in zebrafish models relative to mice still cannot
account for the general trend towards greater neurological
involvement in the fish compared to rodents. Thus, perhaps
factors beyond genetics also serve to manipulate phenotypes in
interferonopathy modeling.
Mind the Microbiome—The Role of the
Experimental Environment
When developing animal models of genetic disorders, often little
attention is paid to the impact of the laboratory environment.
Compared to their wild counterparts, lab mice and zebrafish live
in a controlled environment in an effort to simplify our
understanding of the relationship between genotype and
phenotype. However, there are notable differences in the
husbandry of zebrafish and mice—leading to arguably very
distinct environment and pathogen exposure.
While zebrafish facilities around the world undoubtedly take
great care in optimizing water quality in their aquaria, there is
some evidence that pathogens are present in water across a large
number of centers (74). A recent study reported evidence of a
novel picornavirus-like pathogen transmitted via the
environment—leading to spontaneous activation of interferon
responses in otherwise healthy animals. Infection was associated
with no overt phenotype, but rather was identified using an isg15
transgenic reporter line. Intriguingly, evidence of widespread
viral infection was identified in RNAseq datasets from 92
facilities across the world (74). It would therefore seem that
“asymptomatic” zebrafish infection may be relatively
commonplace in zebrafish research and act as somewhat of a
confounding—although not necessarily unhelpful—factor in
studying immune responses in these animals.
In contrast, mice live in a relatively “clean” environment
compared to their zebrafish counterparts—with sterilization of
bedding, food, and water being commonplace in murine
husbandry. It is unsurprising, therefore, that lab mice are exposed
to significantly fewer pathogens—including viruses—compared
with their wild counterparts, contributing to notable differences in
immune composition and antiviral response (75). This is in stark
contrast to zebrafish and, of course, humans—for whom exposure
to low virulence pathogens is commonplace throughout life and
may even begin in utero (76–79), Perhaps, then, it is the sterile
environment of laboratory mice—in which pathogen exposure is
extremely low—which might explain immune phenotypes that are
notably removed from the human condition.
Possible viral exposure is particularly relevant when modeling
interferonopathies—a collection of disorders that have for so
long been thought to mimic congenital viral infection and
associated with genes involved in the human antiviral
response. While active viral infection is usually excluded before
a diagnosis of AGS or RNaseT2-deficient leukodystrophy can be
made, it is possible that exposure to commonplace, low-virulence
viruses could serve as a risk factor—or even a trigger—for
activation of type I interferon response in patients that are
already genetically predisposed to interferonopathies. It has
been suggested that such viruses may be broadly linked to
neurological pathologies in a manner that is complex and
temporarily removed—this, too, may be the case for
interferonopathies (80). Such viral infections may resolve
without the development of overt phenotypes at the time of
infection—instead, triggering the autoimmune response and
resulting in downstream disability.
Perhaps, this previously unappreciated role of viral infection
as a trigger for interferonopathy can explain why mice, in
general, develop somewhat milder phenotypes, while zebrafish
—with virus exposure even during larval stages—go on to
develop similar pathology to that which we see in humans.
While viral exposure may be particularly relevant to the
interferonopathies—with type I IFNs primarily considered for
their role in antiviral response—bacterial infection is also known
to trigger type I interferon response (81). In mice, deletion of
IFNAR (the type I IFN receptor) has been shown to both protect
against and exacerbate infection with different bacterial species—
demonstrating a clear, albeit complex, role of bacteria in triggering
type I IFN (82, 83). Likewise, in zebrafish, colonization of germ-free
larvae with bacteria has also been shown to upregulate the
interferon-stimulated genes, among other innate immunity-
associated transcripts (84). It is conceivable, therefore, that
environmental exposure to bacteria could also act as a trigger for
interferonopathy pathology in zebrafish and humans in a similar
manner to viruses—further exacerbating differences between
murine and zebrafish pathology.
There have been numerous calls for mice to be raised in
pathogen-rich environments in order to increase the impact of
immune research following a crisis in translation that extends
beyond inferonopathy modeling (66–68, 85). Indeed, research
has suggested that exposing lab mice to a greater number of
environmental pathogens may result in immune responses that
better mimic human phenotypes (68). So-called wildling mice—
mice born to wild mothers but with the same genetic background
as conventional laboratory animals—better predicted patient
response to immune-related therapies in clinical trials
compared to conventional lab animals (68). While the precise
viral exposure of these wildling mice was not assessed, these
animals were maternally exposed to a more diverse microbial
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population than lab mice—suggesting life-long exposure to
pathogens increases the face validity of mouse models in
recapitulating human disease.
One might therefore expect that raising interferonopathy
mouse models with greater pathogen exposure—or inducing
viral infection—in early life may result in a more relevant
neuroinflammatory phenotype. It should be noted that
preliminary experiments inducing immune challenge in both
RNaseH2mutant and SAMHD1 knockout mice failed to find any
difference in response compared to wildtype animals.
SAMHD1-/- mice produced normal levels of IFNa and IFN
response following encephalomyocarditis viral infection, while
RNaseH2 mutant mice developed a similar clinical phenotype as
their wildtype counterparts following induction of experimental
autoimmune encephalomyelitis (16, 21). However, it should be
noted that both of these immune challenges were induced in
adult—rather than developing—animals, and that long-term
downstream effects were not observed. In humans, congenital
infection by HIV-1 is characterized by upregulation of interferon
a alongside intracranial calcification and white matter
abnormalities—a phenotype remarkably similar to that of AGS
—suggesting the timing of infection may well modulate the
severity of pathology (4, 86–88). Thus, it is still entirely
possible similar immune challenges could trigger a
downstream inflammatory phenotype in these mouse models if
performed during embryonic development or in early
postnatal stages.
If asymptomatic, low-virulence viral infection does in fact
trigger interferonopathy in humans, this too may provoke the
type I interferon response observed in zebrafish models. Indeed,
upregulated transcription of isg15—an interferon-stimulated
gene known to be involved in the zebrafish immune response
and the very transgenic reporter line used to identify the novel
picornavirus-like pathogen endemic to zebrafish facilities across
the world—has been reported in samhd1, adar and rnaset2
defective zebrafish models throughout development (23, 38,
74). After hatching (around 2 days post fertilization), zebrafish
larvae may be particularly susceptible to viral infection of the
brain due to lack of a functional blood brain barrier (BBB) (89).
As in mammals, the zebrafish BBB is thought to develop and
become functional in a spatiotemporal manner, with the
hindbrain BBB becoming functional around four days post
fertilization and the midbrain a day later (89). As such, it is
feasible that viruses—or, at least, mediators of the antiviral
response—are able to enter the larval brain and trigger
interferon response. This mechanism could also trigger IFN in
human patients—however, our understanding of human BBB
formation is less well characterized. Although embryonic BBB is
thought to develop and become functional in utero, there is some
suggestion that full maturation (including inclusion of mature
cell types in the neurovascular unit) does not occur until after
birth and, even after maturation, pro-inflammatory cytokines are
able to cross the BBB with possible deleterious effects (90, 91).
Thus, even if the human brain is protected from direct viral
infection, it is conceivable that patients with mutations in AGS-
associated genes are already susceptible to activation of the
interferon response such that the antiviral response initiated by
systemic infection may be sufficient trigger neuropathology by
infiltration of cytokines into the developing brain.
The role of virus exposure in the zebrafish interferon response
could be further dissected by exploiting the ex utero development
of zebrafish embryos to raise animals in a sterile environment.
Bleaching zebrafish eggs at 24 h post-fertilization has been shown
to prevent productive viral infection throughout embryogenesis
and is a strategy commonly used to raise embryos in a pathogen-
free environment (74, 92). If bleached zebrafish mutants were to
show an improved inflammatory phenotype compared to their
conventionally reared counterparts, this would suggest a role for
viral infection in triggering type I interferon response. Thus,
careful modulation of the zebrafish microenvironment could be
informative about the role of viral infection in triggering type I
interferon response in autoimmune interferonopathy.
Recent publications in AGS have suggested that the autoimmune
response observed in these patients is triggered by retroelement-
derived nucleotides (7). If this is the case, manipulating viral
exposure in animal models may well not alter their phenotypes at
all. However, we believe that the reliably more severe neurological
phenotypes present in the zebrafish compared to the mouse—
despite similar genotypes and arguably greater evolutionary
similarity between mice and humans than the zebrafish—suggest
a prominent role for the environment in modulating pathogenesis
of these disorders. These two schools of thought are by no means
mutually exclusive: it is possible that viral infection and the presence
of foreign nucleotides may provide the first trigger for a breakdown
in self-tolerance, whereby individuals develop downstream
autoimmune response to endogenous retroelements-derived
nucleic acids which further drives pathology. Patients with AGS
typically present with severe deterioration during the initial
encephalopathic phase, but then stabilize and—in some cases—
even show some small improvements (7, 69). Similarly, it has also
been reported that some patients with RNaseH2 and RNaseT2
mutations may show normalization of interferon response over
time: initially showing a positive interferon signature that later
becomes negative at follow-up (18). If viral infection is a trigger for
pathology, the initial flurry of antiviral response could explain this
rapid deterioration and upregulation of ISGs, followed by
subsequent stabilization as autoimmunity resolves. In contrast, if
the trigger for pathology is truly endogenous in cause, one might
expect a continued autoimmune response with consistent
deterioration beyond the first year of life. Nonetheless, the points
highlighted above suggest an additional layer of complexity in the
pathogenesis of interferonopathies—or at least, their animal models
—beyond simply genetics.
SUMMARY AND FUTURE PERSPECTIVES
Type I interferonopathies are a group of severe, life-limiting
disorders—characterized by a disturbance of the homeostatic
control of the interferon response and a range of downstream
inflammatory phenotypes. With such profound effect on
development and survival, interferonopathies with neurological
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involvement— including AGS and RNaseT2-deficient
leukoencephalopathy—are particularly debilitating. Yet, despite
their devastating effects, much remains to be understood about
these disorders and, crucially, how to treat them.
Our understanding of these conditions and the development
of novel therapies has thus far been limited by a lack of valid
animal models (8). In this review, we have demonstrated
consistent limitations in animal models across both species in
mimicking the human disease state in AGS. However, mouse
models in particular are limited in their recapitulation of the
human neurological phenotype.
While there are several key differences between these species
specifically relating to each of the AGS-associated genes, we propose
that the disparity between rodent and fish models reflects the
differing laboratory environments in which these animals are
raised, and the corresponding effects on the immune system.
Laboratory mice live in relatively sterile environments, and as
such have an immune system largely removed from their
wildtype counterparts. In contrast, both zebrafish and humans are
exposed to a number of pathogens—including viruses—throughout
early development: we believe this exposure is essential in
modulating the development of interferonopathy neuropathology.
We propose that an initial viral stimulus may serve as the trigger
for type I interferon response in AGS and RNaseT2-deficient
leukoencephalopathy in human patients and corresponding
zebrafish models, leading to subsequent autoimmune pathology
due to a compromised genetic background. The absence of viral
triggers in lab mice could explain why these animals do not develop
the neuroinflammation central to AGS pathology, while the
zebrafish—exposed to viruses throughout embryogenesis—
develop somewhat more robust neurological pathology.
Subsequent work may further explore the effects of viral stimuli
in AGS models across both species.
Nonetheless, the vastly different phenotypes between
zebrafish and rodent models with mutations of the same gene
highlight the importance of model choice, methodological
considerations and, perhaps most importantly, pathogen
exposure when modeling disorders of the immune system.
Future research must carefully consider how these unseen
pathogens—or lack thereof—influence pathology if we are to
ever understand the complex gene-environment interactions that
form human immune response in interferonopathies
and beyond.
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